title: Revolutionary change in rheumatoid arthritis management with biological       therapy.
abstract: Biological agents targeting a specific molecule have extraordinarily fine specificity       and powerful functional capabilities. By the introduction of biological therapy, management of       rheumatoid arthritis has undergone a revolution and a paradigm shift. In this review, I will       summarize the role in the pathogenesis of rheumatoid arthritis of the molecules targeted by       biological agents. Providing evidence obtained in clinical trials and investigator-initiated       clinical studies in Japan, the effectiveness and safety of biological therapy in rheumatoid       arthritis are discussed. Finally, studies aiming at a personalized strategy with biological       agents are listed and the future perspectives toward tailor-made medicine in the field of       rheumatology are discussed.
authors: Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan. tsutake@z5.keio.jp
authors: Tsutomu
authors: T
authors: Takeuchi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D001691:Biological Therapy; D002986:Clinical Trials as Topic; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept